Table 1.
Patient characteristics
| Acalabrutinib (n=35) |
Acalabrutinib+pembrolizumab (n=38) | Total (n =73) |
|
| Age (years); median (range) | 64 (44–78) | 64 (30–80) | 64 (30–80) |
| Sex, n (%) | |||
| Male | 17 (48.6) | 19 (50.0) | 36 (49.3) |
| Female | 18 (51.4) | 19 (50.0) | 37 (50.7) |
| Race, n (%) | |||
| Asian | 1 (2.9) | 1 (2.6) | 2 (2.7) |
| Black or African-American | 3 (8.6) | 1 (2.6) | 4 (5.5) |
| White | 29 (82.9) | 33 (86.8) | 62 (84.9) |
| Other | 2 (5.8) | 3 (7.9) | 5 (6.8) |
| ECOG PS, n (%) | |||
| 0 | 10 (28.6) | 7 (18.4) | 17 (23.3) |
| 1 | 25 (71.4) | 31 (81.6) | 56 (76.7) |
| Disease stage at baseline, n (%) | |||
| I–III | 5 (14.3) | 8 (21.1) | 13 (17.8) |
| IV | 30 (85.7) | 28 (73.7) | 58 (79.5) |
| Missing | 0 | 2 (5.3) | 2 (2.7) |
| Tumor grade, n (%) | |||
| G2 | 10 (28.6) | 9 (23.7) | 19 (26.0) |
| G3 | 1 (2.9) | 5 (13.2) | 6 (8.2) |
| G4 | 5 (14.3) | 9 (23.7) | 14 (19.2) |
| Missing | 19 (54.3) | 15 (39.5) | 34 (46.6) |
| Number of prior systemic regimens, n (%) | |||
| 1 | 9 (25.7) | 7 (18.4) | 16 (21.9) |
| 2 | 9 (25.7) | 10 (26.3) | 19 (26.0) |
| ≥3 | 17 (48.6) | 21 (55.3) | 38 (52.1) |
ECOG PS, Eastern Cooperative Oncology Group Performance Status.